AUROPHARMA

Major investment in biologics manufacturing

1. US acquisition nearing completion Aurobindo Pharma is close to completing the acquisition of US-based generic drug maker Lannett after clearing important regulatory hurdles. The acquisition is expected to strengthen Aurobindo's presence in the US generics market. 2. Strong pipeline of USFDA approvals The company continues to receive multiple USFDA approvals for generic medicines across therapeutic categories. New product launches in the US market remain an important growth driver. 3. Biologics business gaining momentum Aurobindo's biologics subsidiaries are making progress in biosimilars and contract manufacturing. Positive clinical developments and expansion in biologics manufacturing are attracting investor attention. 4. Major investment in biologics manufacturing The company is investing significantly in new biologics manufacturing facilities to support future growth and global partnerships. This is viewed as a long-term diversification strategy beyond traditional generics. 5. Europe and US business showing improvement Sales momentum in key international markets, especially Europe and the US, has remained encouraging. Growth in injectables and specialty products is supporting performance. 6. Share buyback completed recently Aurobindo undertook a sizeable share buyback program during FY26, reflecting management's confidence in the business and capital allocation discipline. 7. Custom manufacturing and specialty products expanding The company continues to focus on: Complex generics Injectables Specialty pharmaceuticals Contract manufacturing opportunities